MSP9

MSP9 (PF3D7_1228600, also called ABRA/p101) is a P. falciparum merozoite surface and parasitophorous vacuole protein that contributes to erythrocyte invasion by directly engaging the host band 3 receptor (PMID:12076769, PMID:14630931, PMID:3042768). Its cysteine-rich N-terminal region binds the exofacial 5ABC region of erythrocyte band 3 specifically and saturably, selecting band 3 over glycophorin A/B and spectrin, with binding abolished by chymotrypsin pretreatment of erythrocytes; two regions of MSP9, Delta1 and Delta2, mediate this interaction and inhibit reinvasion in vitro (PMID:12076769, PMID:14630931). MSP9 does not act alone at the erythrocyte surface: it forms a stable co-ligand complex with MSP1(42), with the MSP9 Delta1a and Delta2 regions contacting the C-terminal MSP1(19)/MSP1(65) portions of MSP1, assembling a ternary MSP1–MSP9–band 3 assembly in which the same MSP9 regions used for complex assembly are those that bind band 3 (PMID:14630931, PMID:16289042, PMID:29511044). MSP9 is a broader component of the schizont/merozoite-stage MSP1-associated surface complex that also includes MSP3, MSP6, MSP7, and rhoptry proteins (PMID:21175202). Independently of its receptor-binding role, MSP9 possesses intrinsic chymotrypsin-like serine protease activity residing in its N-terminal portion and inhibited by chymostatin and PMSF but not leupeptin (PMID:10699251). Antibodies and synthetic peptides directed at the N-terminal region block merozoite reinvasion, marking MSP9 as an invasion-relevant, vaccine-candidate antigen (PMID:11483276, PMID:9596765).

1. 1988 Medium

   Establishing where MSP9 resides was the first step in placing it in the invasion pathway; localization to the merozoite surface and parasitophorous vacuole positioned it at the host–parasite interface.

   Evidence Protein sequencing and immunofluorescence/immunoblot characterization of the cloned antigen (ABRA/p101)

   PMID:3042768

   Open questions at the time

   • Does not define a molecular activity or receptor
   • Complex membership not addressed
2. 2000 Medium

   The question of whether MSP9 had an enzymatic function was answered by demonstrating intrinsic chymotrypsin-like serine protease activity in its N-terminal portion, revealing a catalytic role distinct from receptor binding.

   Evidence In vitro protease assays with fluorogenic/chromogenic substrates and inhibitor profiling using recombinant ABRA fragments

   PMID:10699251

   Open questions at the time

   • No physiological substrate identified
   • Single lab, single study
   • Relationship of protease activity to invasion not tested
3. 2001 Medium

   To test whether the N-terminal region has invasion-relevant erythrocyte affinity, high-affinity binding peptides were mapped and shown to block invasion, functionally implicating that region in host cell engagement.

   Evidence Erythrocyte binding assays and in vitro invasion inhibition with synthetic 20-mer peptides plus affinity measurements

   PMID:11483276

   Open questions at the time

   • Did not identify the erythrocyte receptor
   • Peptide binding may not reflect native protein conformation
4. 1998 Medium

   Whether MSP9 epitopes are functionally accessible during invasion was addressed by showing antipeptide antibodies inhibit reinvasion by ~90%, marking MSP9 as an invasion-blocking target.

   Evidence In vitro invasion inhibition using rabbit antipeptide antibodies with immunoblot confirmation

   PMID:9596765

   Open questions at the time

   • Mechanism of inhibition (steric vs receptor blockade) not resolved
   • Two constructs only
5. 2002 High

   The identity of the MSP9 erythrocyte receptor was resolved by demonstrating specific, saturable binding to band 3 through the cysteine-rich N-proximal region, distinguishing it from other candidate surface proteins.

   Evidence Erythrocyte binding assays with recombinant and native ABRA fragments, deletion constructs, and chymotrypsin controls

   PMID:12076769

   Open questions at the time

   • Precise band 3 epitope not yet mapped at this stage
   • Contribution of protease activity to binding untested
6. 2003 High

   Building on receptor identity, the specific band 3 subregion and the co-ligand nature of MSP9 were defined, showing MSP9 Delta1/Delta2 target the exofacial 5ABC region and that MSP9 acts together with MSP1(42).

   Evidence Recombinant binding assays, soluble 5ABC competition, invasion inhibition, and co-IP of native MSP9 and MSP1(42)

   PMID:14630931

   Open questions at the time

   • Stoichiometry/architecture of the co-ligand complex not resolved
   • How complex assembly relates to invasion kinetics unknown
7. 2005 High

   The molecular interface for MSP9–MSP1 assembly was mapped, showing the same MSP9 Delta1a/Delta2 regions bind MSP1(19)/MSP1(42) and band 3, defining a unified ternary MSP1–MSP9–band 3 complex.

   Evidence Biochemical pulldown/binding assays with recombinant MSP9 deletion constructs against native MSP1(19)/MSP1(42)

   PMID:16289042

   Open questions at the time

   • Whether band 3 and MSP1 binding are simultaneous or competing on the same MSP9 regions not resolved
   • No structural model of the ternary complex
8. 2008 Medium

   Conservation of MSP9 function was tested in a rodent model, showing the P. berghei ortholog retains both erythrocyte binding and protease activity and confers protection on immunization.

   Evidence Erythrocyte binding and protease assays plus mouse immunization/challenge with recombinant PbMSP-9

   PMID:18272263

   Open questions at the time

   • Findings are for the P. berghei ortholog, not the P. falciparum gene
   • Correlate of protection not defined
9. 2010 Medium

   Placing MSP9 in its full surface context, proteomics showed it is a member of a larger stage-specific MSP1-associated complex that also recruits rhoptry proteins.

   Evidence Anti-MSP1 and anti-RhopH3 pulldowns from merozoite lysate followed by tandem mass spectrometry

   PMID:21175202

   Open questions at the time

   • Direct MSP9 contacts with individual complex members beyond MSP1 not established
   • Functional role of MSP9 within the wider complex untested
10. 2018 Medium

    Refining the MSP1 binding site, MSP9 was shown to interact with MSP1(65) (p38/p42) but not MSP1(19), and to be one of only two complex members that bind erythrocytes.

    Evidence Recombinant protein interaction and erythrocyte binding assays with defined MSP1 sub-fragments

    PMID:29511044

    Open questions at the time

    • Apparent discrepancy with earlier MSP1(19) binding data not reconciled
    • Single lab

• The physiological substrate of MSP9's serine protease activity and its causal contribution to invasion versus its receptor-binding role remain unresolved.
• No native protease substrate identified
• No genetic knockout/knockdown phenotype for the P. falciparum gene in the corpus
• No structure of the MSP1–MSP9–band 3 complex